Eric Singhi: My thoughts on the COCOON trial from ELCC25
Eric Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, shared a post on X:
“COCOON data at ELCC25 – can prophylactic enhanced dermatologic management prevent moderate to severe dermatological AEs with amivantamab + lazertinib?
COCOON reaches primary endpoint
Within first 12 weeks,
- G2+ dermatologic AEs low from 76.5% to 38.6%
- G3 dermatologic AEs low from 8.8% to 4.3%
Meaningful slide – scalp lesions remain one of the most challenging dermatologic AEs with this combination.
Encouraging to see about a 70% reduction in G2+ scalp dermatologic AEs (29% v 9%), though small numbers.
Encouraging to see that patients who received prophylactic enhanced dermatologic management had lower AE-related discontinuation rates (11% v 19%).
S/p COCOON and MARIPOSA OS data, my thoughts:
- The hand that prescribes MARIPOSA must schedule a dermatology consult and the prophylactic COCOON regimen.
- Supportive care can effectively keep patients on treatment and is essential to fully realize the benefit we aim for.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023